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Abstract 
 
Objectives  
To explore the relationship between cognitive impairment and conventional measures 
of disability in multiple sclerosis (MS), quality of life (QOL) and employment status 
using the Brief International Cognitive Assessment for MS (BICAMS) in the routine 
outpatient clinic.  
 
Methods 
62 patients with MS were assessed on the Brief International Cognitive Assessment for 
MS (BICAMS) test battery for cognitive impairment. Data was obtained on employment 
status and a number of questionnaires completed including; Fatigue Severity Score 
(FSS), Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), Hospital Anxiety 
and Depression Scale (HADS) the Functional Assessment of MS (FAMS) as well as on the 
EuroQOL five dimension questionnaire (EQ-5D). Other assessments include the Patient 
Activation Measure (PAM-13) and Unidimensional Self-Efficacy scale for MS (USE-MS). 
 
Results 
Cognitive assessment revealed 44 subjects (65%) had evidence of cognitive impairment 
on formal testing. In comparison with patients without evidence of cognitive 
impairment, cognitively impaired patients exhibited significantly higher rates of 
unemployment (p = 0.009). The SDMT was the most significant predictor of 
unemployment.  
 
Cognitive impairment was associated with lower QOL scores on the FAMS (p = 0.001) 
and EQ-5D (p  <0.001). 
 
Conclusion 
BICAMS provides a sensitive and easy to administer screening test for cognitive 
impairment within the outpatient setting. Cognitive impairment is common in our 
cohort of MS patients attending outpatients and appears to be associated with increased 
rates of unemployment and lower measures of quality of life.  
 
  
 
 
Introduction: 
Multiple sclerosis (MS) is a common inflammatory condition affecting the central 
nervous system (CNS) and is the most common cause of acquired, non-traumatic 
disability in young adults 1. As well as the physical disability associated with MS there 
exist significant non-motor manifestations. Rates of depression and cognitive 
dysfunction are higher among patients with MS than the general population 2. Of these, 
cognitive dysfunction is particularly under recognised and currently, presents limited 
opportunity for intervention or treatment. Studies have revealed that cognitive 
impairment is present in 40-65% of individuals with clinically definite MS on 
neuropsychological testing 2. Cognitive impairment has been identified at all stages and 
affects all subtypes of MS. Studies have shown cognitive deficits, (in particular deficits in 
information processing speed, concentration and working memory) to be present in the 
early stages of MS including clinically isolated syndrome (CIS) 3 4. The presence of 
cognitive impairment may therefore provide a measure of diffuse brain pathology early 
in the course of MS.  
 
Cognitive impairment has a broad negative impact on the lives of people with MS 
independent of physical symptoms 5. Perhaps the most severe and far-reaching effect is 
unemployment, which results in extensive personal, social and financial costs. Cognition 
has been linked to unemployment in many countries 6 7. Cognition has been shown to 
mediate the effects of disability on employment status 8. Within 10 years of diagnosis, 
about 50% of people with MS are unemployed 9.  
 
It is clearly important to identify people with MS who may be at risk of unemployment 
so that appropriate management strategies can be put in place 10. There are a number of 
cognitive test batteries that can be used to identify cognitive impairment in MS 11 12. The 
Brief International Cognitive Assessment for MS (BICAMS) is a brief (15-minute) 
screening tool for health care professionals to identify cognitive impairment in MS 13. 
BICAMS comprises the first five learning trials of the California Verbal Learning Test II 
(CVLT-II), the first three recall trials Brief Visuospatial Memory Test Revised (BVMT-R) 
and the Symbol Digits Modalities Test (SDMT) 14.  
 
 
 
This study was designed to explore the utility of BICAMS in the outpatient clinic to 
identify cognitive impairment and examine how cognitive impairment relates to 
disability, employment and quality of life measures in our patient population.  It 
provides the first UK data on the application of BICAMS in relation to many of these 
measures including employment status.  
  
 
 
Subjects and Methods 
 
Participants  
Sixty-two patients (43 female, 19 male) were included in the study between February 
2014 and February 2015. Participants were recruited through outpatient clinics while 
attending for routine Neurology outpatient appointments at Brighton and Sussex 
University Hospitals NHS Trust (BSUH). Those with cognitive impairment went on to 
participate in a study cognitive rehabilitation. We report here the baseline data of all 
patients screened. 
 
All participants signed informed written consent before undergoing testing. The study 
was approved by the Northern Ireland Research Ethics Committee. Inclusion criteria 
were as follows: (a) age between 18 and 65, (b) clinically definite MS, according to the 
McDonald criteria 15. All participants underwent a detailed neurological assessment 
including Kurtzke Expanded Disability Status Scale (EDSS) 16 scoring by an EDSS 
certified neurologist (http://www.neurostatus.net).  
 
Patients were excluded if they had a history of significant psychiatric disorders, alcohol 
or drug abuse, visual acuity less than 6/18 corrected, oscillopsia or diplopia that would 
interfere with testing. Patients were also excluded if they had a MS relapse, received 
corticosteroids, or had changes made to antidepressants or psychoactive medications 
within the previous month.  
 
Cognitive and Behavioural Assessment 
Participants underwent neuropsychological assessment and were defined as having 
cognitive impairment if they scored below the 5th centile for normative data (adjusted 
for age, sex and years of formal education) on one or more of the BICAMS tests 17.   
 
Patients also completed the following assessments: EuroQOL five dimension 
questionnaire (EQ5D-5L), a generic health-related quality of life scale 18, Functional 
Assessment of MS (FAMS) (an MS specific quality of life scale) 19, Patient Activation 
Measure (PAM-13) (a 13 item generic scale for chronic illness management), and a 
measure of patient empowerment in MS 20, Unidimensional Self-Efficacy scale for MS 
 
 
(USE-MS) 21, the Hospital Anxiety and Depression Scale (HADS) 22, Multiple Sclerosis 
Neuropsychological Questionnaire (MSNQ) (a patient self-reported measure of 
cognitive function) 23, and the Fatigue Severity  Scale 24.   
 
 
Statistical Analysis  
Descriptive statistics for normally distributed continuous variables are expressed as 
mean and standard deviation. Skewed continuous variables were summarised using 
median and interquartile range (IQR). Categorical variables are summarised by  
frequencies and percentages.  
 
Those patients with cognitive impairment were compared to those without cognitive 
impairment across a number of variables.  
 
Normality of continuous variables was assessed using the Kolmogorov-Smirnov test.  
 
 Categorical variables were compared by the Pearson 2 test. The means of continuous 
variables were compared using the independent samples t-test or the Mann-Whitney U 
test for skewed data.   
All tests were two-tailed; p-values less than 0.05 were considered significant. 
Analyses were performed using SPSS version 21 (Armonk, NY: IBM Corp).    
  
 
 
Results  
Demographic and Cognitive Outcomes 
62 patients underwent clinical and neuropsychological assessment. 40 patients (65%) 
showed evidence of cognitive impairment, as defined as scoring below the 5th centile for 
normative data on one or more of the BICAMS scales 17. 
 
At entry, 44 patients (71%) had relapsing remitting MS (RRMS) and 18 patients (29%) 
had secondary progressive MS (SPMS). Participants were aged between 31 and 63 years 
of age. The mean (SD) age of participants was 49.35 (8.88) years, range was 31 to 63 
years. The mean (SD) duration of MS from diagnosis to enrolment was 12 (8.0), range 1 
to 40 years. Median EDSS was 4.0 (range 1.0–6.5). Thirty-one participants (50%) were 
on disease modifying therapy (DMT) at enrolment (natalizumab n=7, beta-Interferon 
n=9, glatiramer acetate n=2, fingolimod n=11 and teriflunomide n=2).  
 
Among the cognitively impaired patients, 21 (53%) failed one test, 11 (28%) failed two 
tests and 8 (20%) failed all three tests of the BICAMS test battery. The most frequently 
failed exam was the SDMT with 56% of all patients scoring below the 5th centile, 29% 
failed the CVLT-II and 23% failed the BVMT-R.  
 
Baseline and demographic characteristics of the two groups (cognitively impaired 
versus non-cognitively impaired) are shown in table 1. Gender, age, education, duration 
of illness, treatment with disease modifying therapy and EDSS did not differ 
significantly between the groups. Overall 27 (44%) of patients were in employment 
however, patients with cognitive impairment on one or more tests were significantly 
more likely to be unemployed with an OR (95% CI) of 4.5, (1.5 to 13.6). Greater rates of 
unemployment were associated with increased number of tests failed (p=0.011) (see 
figure 1). The odds ratio of being unemployed with patients failing on 1, 2 and 3 tests 
increased to 4.3, 5.7 and 6.4 respectively.  
 
  
 
 
The SDMT score was found to be the most significant predictor of unemployment (table 
2). The strength of association did not change significantly when adjusting for other 
variables.  
 
Rates of unemployment were seen to increase with lower performance on the SDMT 
(figure 2). 
 
 
 
 
 
Table 1: Characteristics by group 
 Normal Cognitive 
Performance (n=22) 
Cognitively 
Impaired (n=40) 
  
 Mean (SD) Mean (SD) Mean difference (95% CI) p 
Age (years) 51.27 (9.70) 48.30 (8.33) 2.97 (-1.72 to 7.66) 0.210 
Disease duration (years) 10.77 (7.30) 12.65 (8.21) 2.10 (-6.07 to 2.32) 0.375 
EDSS 3.48  (1.74) 4.34  (1.70) -0.86 (-1.77 to 0.05) 0.065 
Education (years) 14.05  (2.34) 13.80 (2.78) 0.25  (-1.15 to 1.64) 0.614 
 
 N/22 (%)  N/40 (%)  Odds ratio (95% CI) p 
Gender (female) 15 (68.2) 28 (70) 1.09 (0.35 to 3.35) 0.882 
Unemployed  7   (31.8) 28 (70) 5.00 (1.63 to 15.38) 0.009 
Disease subtype: 
        Relapsing-remitting  
        Secondary-progressive  
 
17 (77.3) 
5   (22.7) 
 
27 (67.5) 
13 (32.5) 
 
0.61 (0.19 to 2.02) 
 
0.417 
 On treatment at enrolment 
to study  
      Interferon * 
      Glatiramer Acetate 
      Fingolimod   
      Natalizumab 
      Teriflunomide  
 12 (54.5) 
 
3 
2 
6 
0 
1 
19 (47.5) 
 
6 
0 
5 
7 
1 
0.75 (0.266 to 2.14) 0.596 
*Includes Interferon (IF)-1b SC, IF-1A IM and IF-1A SC 
 
 
 
 
Table 2: Univariate analysis of employment status vs cognitive impairment.  
 
 Employed (n=27) Unemployed (n=35)   
 Mean (SD)  Mean (SD) Mean difference (95% CI) p 
SDMT 53.3 (10.4)  39.5 (9.5) 13.79 (8.72 to 18.86) <0.001 
CVLT 52.5 (12.6)  46.2 (9.6) 6.28   (0.65 to 11.91) 0.029 
BVMT 24.9 (6.9) 19.4 (6.8) 5.51  (2.02 to 9.02) 0.03 
SDMT: Symbol Digits Modalities Test; CVLT: California Verbal Learning Test; BVMT-R: Brief Visuospatial 
Memory Test Revised. 
 
When adjusting for potential confounding variables (age and years of formal education) 
the strength of association did not change significantly (p<0.01).  
 
  
 
 
 
 
Figure 1: BICAMS performance and employment 
Rates of employment versus number of tests failed showing increasing rates of 
unemployment the more BICAMS tests that are impaired. 
 
  
 
 
 
Quality of life and behavioural data 
Patients with cognitive impairment had significantly lower FAMS scores (p=0.001) 
(indicating lower QOL), higher EQ-5D scores (p<0.001) (indicating lower QOL) and 
higher MSNQ (p=0.004) scores in keeping with a greater subjective perception of 
cognitive impairment. Quality of life and behaviour outcome measures are shown in 
table 3. Quality of life measures were seen to improve with increasing performance on 
the SDMT (figure 3).  
 
 
 
Figure 2: Rates of employment with increasing performance on SDMT 
SDMT score versus rate of employment showing increasing rates of employment with higher 
SDMT scores.  
 
  
 
 
Table 3: Quality of life and behavioural measures 
 Normal Cognitive 
Performance (n=22) 
Cognitively Impaired 
(n=40) 
  
 Mean (SD) Mean (SD)  Mean difference (95% CI) p 
FAMS 117.1 (23.7) 90.9 (30.9) 26.12 (10.95 to 41.29) 0.001  
PAM-13 64.9 (13.1) 61.8 (17.0) 3.04 (-5.35 to 11.44) 0.471 
EQ5D 8.6 (2.6) 11.8 (3.3) -3.18 (-4.82 to -1.55) <0.001 
USE-MS 20.3 (5.2) 17.4 (6.8) 2.86 (-0.45 to 6.18) 0.089 
MSNQ 27.1 (10.5) 35.6 (12.2) -8.56 (-14.73 to -2.38) 0.007 
HADS-D 7.2 (3.6) 9.0 (3.3) -1.80 (-3.60 to 0.01) 0.050 
HADS-A 7.5 (5.2) 9.2 (4.7)  -1.65 (-4.24 to 0.94) 0.208 
FSS 45.81 (9.5) 50.4 (11.9) -4.54 (-10.54 to 1.46) 0.136 
FAMS: Functional Assessment of MS; PAM-13: Patient Activation Measure; EQ5D: EuroQOL five dimension questionnaire; 
USE-MS: Unidimensional Self-Efficacy scale for MS; MSNQ: Multiple Sclerosis Neuropsychological Questionnaire; HADS-D: 
Hospital Anxiety and Depression Scale (depression); HADS-A: Hospital Anxiety and Depression Scale (anxiety);  FSS: Fatigue 
Severity Scale; 
  
 
 
 
Figure 3:  Relationship between SDMT score and QOL measures 
Graph showing increase mean (95% CI) FAMS score (indicating better QOL) with 
increasing SDMT performance.  
 
  
 
 
Discussion 
Cognitive impairment is common among patients with MS. The incidence of cognitive 
impairment in our cohort of MS patients attending outpatients at 65% was similar to 
that previously reported elsewhere 2.  
 
Rates of unemployment have been shown to increase over time in patients with MS and 
presents significant cost implications to the individual and society 25. Various risk 
factors for unemployment in MS have been identified including, low education level, 
extent of disability, progressive subtype and personality as well as cognitive 
impairment 7 26.  
 
BICAMS provides a sensitive and easy to conduct means of identifying cognitive 
impairment in the outpatient setting and may provide a means for identification of 
patients with other, more complex psychosocial needs. This study provides the first UK 
data pertaining to the use of BICAMS in assessing employment status within a UK 
cohort.  Factors linked to unemployment in our study were advanced age and disease 
duration, increased disability and cognitive impairment. Of these, the SDMT was the 
most significant predictor of unemployment. The strength of association did not change 
significantly when adjusting for other variables. 
 
Of the tests utilised within BICAMS, the SDMT may provide among the most sensitive 
measures of cognitive impairment in MS 27. Previous work examining cognitive 
impairment in relation to employment in MS had identified the SDMT to also be one of 
the main predictors of employment status 6 7 28; the CVLT-II has also predicted reduced 
employment status in a longitudinal study 7. Although simple strategies may overcome 
memory deficits, at least when they are mild, the “bandwidth” limitations of reduced 
information processing speed are less easy to manage.  
  
 
 
Patients with MS have consistently been shown to have a reduced quality of life with 
multiple factors related to the disease such as disability, pain, fatigue, personality, 
depression and unemployment likely to be implicated 28 29. Cognitive impairment has 
been shown to negatively impact upon QOL independent of physical disability 5 and 
employment status has been more closely linked to QOL than EDSS 30.  
 
In our study there was a statistically significant difference in QOL between those 
patients with cognitive impairment compared to those without as measured on both the 
MS specific QOL scale, (FAMS) as well as a generic QOL scale (EQ-5D). A better 
understanding of the specific cognitive deficits in MS has led to more sensitive patient 
reported measures being developed in which relatively close correlation is seen 
between subjective measures of cognitive impairment and objective outcomes 23. 
Recent work has also suggested that patient reported perceptions of cognitive 
difficulties may be predictive of unemployment status independent of mood and 
objective memory performance 6. This finding may reflect a relative insensitivity of 
standard tests to subtle cognitive impairments at a time when “sub-clinical” cognitive 
impairment is beginning to cause difficulties with work.  
 
To explore this, we utilised the Multiple Sclerosis Neuropsychological Questionnaire 
(MSNQ), a patient self-reported measure perceived competency with activities of daily 
living and day-to-day cognitive tasks 23. Cognitively impaired patients had significantly 
lower MSNQ scores than patients without cognitive impairment.  
 
How best to manage cognitive impairment is, at present, far from clear. However on a 
clinical basis, early identification of cognitive impairment allows identification of 
patients who are at risk of employment difficulties, which may enable support to be put 
in place that enables them to continue in their current employment with 
accommodations 10. This will extend their time in employment and potentially allow 
them to avoid having employment terminated for poor performance.  Instead 
individuals might achieve medical retirement, a better personal and financial outcome 
in most countries.  More broadly, by identifying patients who may struggle with disease 
management, more optimal communication strategies and monitoring protocols can be 
adopted to reduce the morbidity associated with cognitive impairment 5.  
 
 
 
Limitations of this current study are that it involved a relatively small cohort and was 
cross-sectional in nature. Through recruiting patients from a specialist clinic there does 
exist the potential for selection bias (possibly reflecting more complex or patients with 
more highly active disease).  
 
Other limitations include the retrospective acquisition of the employment data, a lack of 
descriptive data pertaining to employment status such as full-time versus part-time 
employment and details pertaining to when an individual ceased to be in employment 
and how this relates to duration of illness. The type of employment (e.g. professional 
versus manual occupations) may also be impacted upon differently by cognitive 
impairment. Future work might examine these factors in detail.  
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Current research questions: 
 What is the pathophysiology of cognitive impairment in multiple sclerosis?  
 What is the relationship between cognitive impairment and employment status 
in multiple sclerosis?  
 What are the optimum interventions to ameliorate the negative impact of 
cognitive impairment in multiple sclerosis?  
 
Main messages:  
 Cognitive impairment is common in patients with multiple sclerosis  
 Cognitive impairment is associated with increased rates of unemployment  
 Cognitive impairment is associated with lower measures of quality of life and 
may be partly independent of physical disability.  
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